FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Haruki Kaku

Research Profile

Disorders

Anatomy

Tumor Cell Line

Chemicals & Drugs

Procedures

Genetic Therapy

Living Beings

Physiology

Gene Expression Regulation, Neoplastic

Concepts & Ideas

Survival Rate

Co-author Network

Publications

TOP 3
Aya Nakamura; Yasutomo Nasu; Tomoko Sako; Morito Sugimoto; Masami Watanabe; Kazushi Ishii; Haruki Kaku; Sabina Mahmood; Atsushi Nagai; Hiromi Kumon
Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder.
Morito Sugimoto; Hideo Ueki; Masami Watanabe; Nam-Ho Huh; Haruki Kaku; Shun-Ai Li; Yasutomo Nasu; Hirofumi Noguchi; Masakiyo Sakaguchi; Hiromi Kumon
Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy.
Takeshi Hirata; Nam-Ho Huh; Haruki Kaku; Yasuyuki Kobayashi; Yasutomo Nasu; Masakiyo Sakaguchi; Kohji Takei; Masami Watanabe; Hiroshi Yamada; Hiromi Kumon
REIC/Dkk-3-encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Haruki Kaku (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Aya Nakamura; Yasutomo Nasu; Tomoko Sako; Morito Sugimoto; Masami Watanabe; Kazushi Ishii; Haruki Kaku; Sabina Mahmood; Atsushi Nagai; Hiromi Kumon
Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder.
Endocrine journal 2013;60(3):275-81.
2012: Morito Sugimoto; Hideo Ueki; Masami Watanabe; Nam-Ho Huh; Haruki Kaku; Shun-Ai Li; Yasutomo Nasu; Hirofumi Noguchi; Masakiyo Sakaguchi; Hiromi Kumon
Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy.
Oncology reports 2012;28(5):1645-52.
2012: Takeshi Hirata; Nam-Ho Huh; Haruki Kaku; Yasuyuki Kobayashi; Yasutomo Nasu; Masakiyo Sakaguchi; Kohji Takei; Masami Watanabe; Hiroshi Yamada; Hiromi Kumon
REIC/Dkk-3-encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer.
International journal of oncology 2012;41(2):559-64.
2012: Hideo Ueki; Masami Watanabe; Hiroshi Yamada; Takeshi Hirata; Peng Huang; Haruki Kaku; Yuji Kashiwakura; Shun-Ai Li; Yasutomo Nasu; Hirofumi Noguchi; Kazuhiko Ochiai; Kohji Takei; Hiromi Kumon
A novel gene expression system for detecting viable bladder cancer cells.
International journal of oncology 2012;41(1):135-40.
2012: Peng Huang; Haruki Kaku; Jie Chen; Yanqun Na; Yasutomo Nasu; Takashi Saika; Katsumi Sasaki; Hideo Ueki; Lei Wang; Masami Watanabe; Ken Yamaguchi; Kai Zhang; Hiromi Kumon
Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence.
Medical oncology (Northwood, London, England) 2012;29(2):829-34.
2012: Keiichiro Kawauchi; Peng Huang; Nam-Ho Huh; Haruki Kaku; Yasutomo Nasu; Kazuhiko Ochiai; Masakiyo Sakaguchi; Kasumi Sasaki; Masami Watanabe; Hiromi Kumon
Preclinical safety and efficacy of in situ REIC/Dkk-3 gene therapy for prostate cancer.
Acta medica Okayama 2012;66(1):7-16.
2011: Masami Watanabe; Peng Huang; Haruki Kaku; Yuji Kashiwakura; Yasuyuki Kobayashi; Yasutomo Nasu; Kazuhiko Ochiai; Katsumi Sasaki; Hideo Ueki; Hiromi Kumon
Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging.
Oncology reports 2011;26(4):769-75.
2011: Kazuhiko Ochiai; Masakiyo Sakaguchi; Hideo Ueki; Masami Watanabe; Yasuyuki Fujii; Takeshi Hirata; Peng Huang; Nam-ho Huh; Haruki Kaku; Yuji Kashiwakura; Yasutomo Nasu; Hirofumi Noguchi; Hiromi Kumon
Tumor suppressor REIC/Dkk-3 interacts with the dynein light chain, Tctex-1.
Biochemical and biophysical research communications 2011;412(2):391-5.
2010: Kai Zhang; Masami Watanabe; Yuji Kashiwakura; Shun-Ai Li; Kohei Edamura; Peng Huang; Ken Yamaguchi; Yasutomo Nasu; Yasuyuki Kobayashi; Masakiyo Sakaguchi; Kazuhiko Ochiai; Hiroshi Yamada; Kohji Takei; Hideo Ueki; Nam-ho Huh; Ming Li; Haruki Kaku; Yanqun Na; Hiromi Kumon
Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development.
International journal of oncology 2010;37(6):1495-501.
2010: P Huang; Haruki Kaku; J Chen; Yuji Kashiwakura; Takashi Saika; Yasutomo Nasu; Y Urata; Toshiyoshi Fujiwara; Masami Watanabe; Hiromi Kumon
Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.
Cancer gene therapy 2010;17(7):484-91.
2009: Jie Chen; Masami Watanabe; Peng Huang; Masakiyo Sakaguchi; Kazuhiko Ochiai; Yasutomo Nasu; Mamoru Ouchida; Nam-ho Huh; Kenji Shimizu; Yuji Kashiwakura; Haruki Kaku; Hiromi Kumon
REIC/Dkk-3 stable transfection reduces the malignant phenotype of mouse prostate cancer RM9 cells.
International journal of molecular medicine 2009;24(6):789-94.
2009: Jie Chen; Peng Huang; Haruki Kaku; Kai Zhang; Masami Watanabe; Takashi Saika; Yasutomo Nasu; Hiromi Kumon
A comparison of proteomic profiles changes during 17beta-estradiol treatment in human prostate cancer PC-3 cell line.
Cancer genomics & proteomics 2009;6(6):331-5.
2008: Tomoko Kobayashi; Masakiyo Sakaguchi; Ryuta Tanimoto; Fernando Abarzua; Mikiro Takaishi; Haruki Kaku; Ken Kataoka; Takashi Saika; Yasutomo Nasu; Masahiro Miyazaki; Hiromi Kumon; Nam-ho Huh
Mechanistic analysis of resistance to REIC/Dkk-3-induced apoptosis in human bladder cancer cells.
Acta medica Okayama 2008;62(6):393-401.
2008: P Huang; Masami Watanabe; Haruki Kaku; Yuji Kashiwakura; J Chen; Takashi Saika; Yasutomo Nasu; T Fujiwara; Y Urata; Hiromi Kumon
Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
Cancer gene therapy 2008;15(5):315-22.
2007: Takanori Murakami; Shin Ebara; Takashi Saika; Shin Irie; Katsuji Takeda; Yoshio Maki; Sadayuki Miyaji; Daisuke Manabe; Haruki Kaku; Yasutomo Nasu; Tomoyasu Tsushima; Hiromi Kumon
Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus calmette-guerin therapy.
Acta medica Okayama 2007;61(6):341-4.
2007: Fernando Abarzua; Masakiyo Sakaguchi; Ryuta Tanimoto; Hiroyuki Sonegawa; Dai-Wei Li; Kohei Edamura; Tomoko Kobayashi; Masami Watanabe; Yuji Kashiwakura; Haruki Kaku; Takashi Saika; Keiichiro Nakamura; Yasutomo Nasu; Hiromi Kumon; Nam-ho Huh
Heat shock proteins play a crucial role in tumor-specific apoptosis by REIC/Dkk-3.
International journal of molecular medicine 2007;20(1):37-43.
2007: Yasutomo Nasu; Takashi Saika; Shin Ebara; Nobuyuki Kusaka; Haruki Kaku; Fernando Abarzua; Daisuke Manabe; Timothy C Thompson; Hiromi Kumon
Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(4):834-40.
2006: Haruki Kaku; Takashi Saika; Tomoyasu Tsushima; Shin Ebara; Takashi Senoh; Toyoko Yamato; Yasutomo Nasu; Hiromi Kumon
Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
The Prostate 2006;66(4):439-44.
2006: Haruki Kaku; Takashi Saika; Tomoyasu Tsushima; Atsushi Nagai; Teruhiko Yokoyama; Fernando Abarzua; Shin Ebara; Daisuke Manabe; Yasutomo Nasu; Hiromi Kumon
Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer.
Acta medica Okayama 2006;60(1):43-9.
2005: Kohei Edamura; Takashi Saika; Takashi Senoh; Fumihito Koizumi; Daisuke Manabe; Shin Ebara; Haruki Kaku; Teruhiko Yokoyama; Fernando Abarzua; Atsushi Nagai; Yasutomo Nasu; Tomoyasu Tsushima; Hiromi Kumon
Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute.
Acta medica Okayama 2005;59(5):195-9.
2004: Kyouhei Kurose; Masakiyo Sakaguchi; Yasutomo Nasu; Shin Ebara; Haruki Kaku; Reiko Kariyama; Yujirou Arao; Masahiro Miyazaki; Tomoyasu Tsushima; Masayoshi Namba; Hiromi Kumon; Nam-ho Huh
Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma.
The Journal of urology 2004;171(3):1314-8.
2003: Takashi Saika; Tomoyasu Tsushima; Yasutomo Nasu; Ryoji Arata; Haruki Kaku; Naoki Akebi; Nobuyuki Kusaka; Hiromi Kumon
Anterior urethral recurrence of superficial bladder cancer: its clinical significance.
Acta medica Okayama 2003;57(6):293-7.
2002: Haruki Kaku; Tomoyasu Tsushima; Yasutomo Nasu; Hiromi Kumon
[Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
Nihon rinsho. Japanese journal of clinical medicine 2002;60 Suppl 11():182-7.
2002: Takashi Saika; Tomoyasu Tsushima; Yasutomo Nasu; Ryoji Arata; Haruki Kaku; Nobuyuki Kusaka; Hiromi Kumon
Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy.
Japanese journal of clinical oncology 2002;32(11):461-5.
2002: Shin Ebara; S Shimura; Yasutomo Nasu; Haruki Kaku; Hiromi Kumon; Guang Yang; Jianxiang Wang; Terry L Timme; Estuardo Aguilar-Cordova; Timothy C Thompson
Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Prostate cancer and prostatic diseases 2002;5(4):316-25.